←
Formation Bio236 posts
Formation Bio avatar

Formation Bio

@formationbio

AI-native pharma company, bringing new treatments to patients faster and more efficiently.

◷ Joined November 2014▧ 104 Photos and videos
Ben Liu avatar
⟳ Formation Bio retweeted
Ben Liu@BenjamineYLiu·Nov 13

One of the world's largest companies will be one that helps you live longer and healthier. Really enjoyed reading this deep dive by @a16z on how AI will reshape Pharma! @vintweeta @aleximm @CarolineGoggs

Alex Immerman @aleximm Nov 13 Article Big Pharma Can Rival Big Software Eli Lilly is worth more than a trillion dollars. There are more than 300 drugs globally projected to generate over $1B each in annual sales (“blockbuster” drugs).¹ Meanwhile, developing a successful

Ben Liu avatar
⟳ Formation Bio retweeted
Ben Liu@BenjamineYLiu·Nov 13

Thanks @bradloncar and @BiotechTV for having me on to share more about @formationbio

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @formationbio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - a step in its plan to make drug development more efficient and become 'the next pharma'. @BenjamineYLiu Watch the full video: biotechtv.com/post/formation…

5:01
BiotechTV avatar
⟳ Formation Bio retweeted
BiotechTV@BiotechTV·Nov 12

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @formationbio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - a step in its plan to make drug development more efficient and become 'the next pharma'. @BenjamineYLiu Watch the full video: biotechtv.com/post/formation…

5:01
Forbes avatar
⟳ Formation Bio retweeted
Forbes@Forbes·Oct 28

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right. Read more: forbes.com/sites/innovationr… 📸: Guerin Blask for Forbes

Post attachment
Formation Bio avatar
Formation Bio@formationbio·Oct 28

Learn more about our new $600M Formation Bio Drug Development Accelerator Fund here.

Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund. @lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development. As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients. Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.

4:18
Formation Bio avatar
Formation Bio@formationbio·Oct 19

(3/3) Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. When asked a plain language question, Phyla pulls the gene record, checks clinical precedent, computes tissue-specific expression, and runs mechanistic analysis over the results — returning an answer with every claim traced to a source. Here’s how we built it, and how it’s used at Formation: formation.bio/blog/phyla

0:38
Formation Bio avatar
Formation Bio@formationbio·Oct 19

(2/3) In an audit of claims, Phyla led on every target-disease pair. 92% of Phyla’s claims were fully backed by the source it cited, vs. 80% (Claude Science) and 67% (GPT-Rosalind).

Post attachment
Formation Bio avatar
Formation Bio@formationbio·Oct 19

(1/3) Phyla is Formation Bio’s context layer for causal biology. We benchmarked it against Claude Science and GPT-Rosalind on writing full research dossiers for 7 drug target–disease pairs, and the results are in. 99.7% of Phyla’s statements carried a citation, compared to Claude Science: 87% (Claude Science) and 86% (GPT-Rosalind). Phyla never dropped below 99.3% on any pair.

Post attachment
Formation Bio avatar
Formation Bio@formationbio·Oct 16

Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. Benchmarked against two other frontier AI life-science platforms, writing full research dossiers across 7 target–disease pairs: 99.7% of Phyla’s statements carried a citation (vs. 87% and 86%), and 92% of its claims were fully backed by the cited source (vs. 80% and 67%). See how we built it, and how it’s being used at Formation: formation.bio/blog/phyla

Post attachment
Formation Bio avatar
Formation Bio@formationbio·Oct 14

“As a company in the era of AI, you should have a thesis for what predictions will happen first, what will happen last, and make sure your company strategy absorbs this as a net tailwind versus a headwind.” Our thesis: AI will improve drug discovery first, toxicity next, and clinical efficacy last. Our CEO @BenjamineYLiu explores this in his Uneven Frontiers essay – link in comments.

0:55
Formation Bio avatar
Formation Bio@formationbio·Sep 18

Formation Bio made #7 on @FastCompany's Best Workplaces for Innovators 2026. This piece highlights one of our internal systems: ARK (AI-ready Repository of Knowledge), our in-house AI platform that connects all internal systems and data across the company. Full write-up here: fastcompany.com/91591991/for… Our open roles: formation.bio/careers Learn more about ARK: formation.bio/blog/ark-mcp-g…